Nasdaq · CIK 0000749647
IMNN Imunon, Inc.
Insider trading from SEC Form 4. Last filing 15 d ago. Close $1.08 on Oct 9, 2026, +1% from the 52-week low and -79% from the high.
Imunon, Inc. (IMNN) has 47 SEC Form 4 filings on file from 10 insiders, the latest filed on Sep 28, 2026. In the last 90 days insiders made 0 open-market buys worth $0 and 1 open-market sell worth $3,950, net -$3,950.
3 open-market trades have been scored at IMNN. The newest: Susan Eylward (General Counsel and Corp Sec) sold $3,950 of stock on Aug 31, 2026, filed Sep 1, 2026, scored 25 (weak). The largest of the 3 shown: Donald P Braun (director) bought $29k on Aug 20, 2024, scored 30 (weak).
IMNN closed at $1.08 on Oct 9, 2026, 1% above its 52-week low and 79% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Imunon, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 25Weak | Susan Eylward General Counsel and Corp Sec sell | $3,950 2,525 shares | -47% | - | |
| 35Weak | Susan Eylward General Counsel and Corp Sec sell | $21k 11,800 shares | -80% | +5% from low-83% from high | |
| 30Weak | Donald P Braun director buy | $29k 25,000 shares | +4188% | - |
Transactions
The newest 50 of 54 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 25, 2026 | Michael H Tardugno Executive Chairman of Board | AGrant or award Common Stock | +7,169 | $1.41 | $10k | 103,921 | 15 d ago |
| Sep 25, 2026 | Douglas Vincent Faller Chief Medical Officer | AGrant or award Common Stock | +4,390 | $1.41 | $6,190 | 45,678 | 15 d ago |
| Sep 25, 2026 | Stacy Lindborg President and CEO | AGrant or award Common Stock | +6,697 | $1.41 | $9,443 | 113,197 | 15 d ago |
| Sep 11, 2026 | Stacy Lindborg President and CEO | AGrant or award Common Stock | +5,504 | $1.47 | $8,091 | 105,580 | 28 d ago |
| Sep 11, 2026 | Michael H Tardugno Executive Chairman of Board | AGrant or award Common Stock | +5,824 | $1.47 | $8,561 | 95,699 | 28 d ago |
| Sep 11, 2026 | Douglas Vincent Faller Chief Medical Officer | AGrant or award Common Stock | +4,211 | $1.47 | $6,190 | 41,288 | 28 d ago |
| Aug 28, 2026 | Susan Eylward General Counsel and Corp Sec | AGrant or award Common Stock | +2,525 | $1.60 | $4,040 | 5,421 | 42 d ago |
| Aug 28, 2026 | Stacy Lindborg President and CEO | AGrant or award Common Stock | +6,822 | $1.60 | $11k | 100,076 | 42 d ago |
| Aug 28, 2026 | Douglas Vincent Faller Chief Medical Officer | AGrant or award Common Stock | +3,626 | $1.60 | $5,802 | 37,077 | 42 d ago |
| Aug 28, 2026 | Michael H Tardugno Executive Chairman of Board | AGrant or award Common Stock | +7,371 | $1.60 | $12k | 89,875 | 42 d ago |
| Aug 31, 2026 | Susan Eylward General Counsel and Corp Sec | SOpen-market sale Common Stock | -2,525 | $1.56 | $3,950 | 2,896 | 42 d ago |
| Jun 25, 2026 | Susan Eylward General Counsel and Corp Sec | AGrant or award Common Stock | +14,696 | $1.72 | $25k | 14,696 | Jun 29, 2026 |
| Jun 25, 2026 | Douglas Vincent Faller Chief Medical Officer | AGrant or award Common Stock | +21,896 | $1.72 | $38k | 21,896 | Jun 29, 2026 |
| Jun 29, 2026 | Susan Eylward General Counsel and Corp Sec | SOpen-market sale Common Stock | -11,800 | $1.75 | $21k | 2,896 | Jun 29, 2026 |
| May 22, 2026 | James E Dentzer director | AGrant or award Common Stock | +11,148 | $2.20 | $25k | 14,963 | May 27, 2026 |
| May 22, 2026 | Frederick J. Fritz director | AGrant or award Common Stock | +10,330 | $2.20 | $23k | 14,097 | May 27, 2026 |
| May 22, 2026 | Donald P Braun director | AGrant or award Common Stock | +5,011 | $2.20 | $11k | 9,319 | May 27, 2026 |
| Jan 2, 2026 | Kimberly Bragg CFO | AGrant or award Stock Option (Right to Buy)derivative | +9,050 | $0.00 | $0 | 9,050 | Jan 6, 2026 |
| Jan 2, 2026 | Donald P Braun director | AGrant or award Stock Option (Right to Buy)derivative | +5,881 | $0.00 | $0 | 5,881 | Jan 6, 2026 |
| Jan 2, 2026 | James E Dentzer director | AGrant or award Stock Option (Right to Buy)derivative | +4,405 | $0.00 | $0 | 4,405 | Jan 6, 2026 |
| Jan 2, 2026 | Khursheed Anwer Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +15,736 | $0.00 | $0 | 15,736 | Jan 6, 2026 |
| Jan 2, 2026 | Susan Eylward General Counsel and Corp Sec | AGrant or award Stock Option (Right to Buy)derivative | +8,251 | $0.00 | $0 | 8,251 | Jan 6, 2026 |
| Jan 2, 2026 | Douglas Vincent Faller Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +12,667 | $0.00 | $0 | 12,667 | Jan 6, 2026 |
| Jan 2, 2026 | Frederick J. Fritz director | AGrant or award Stock Option (Right to Buy)derivative | +5,892 | $0.00 | $0 | 5,892 | Jan 6, 2026 |
| Jan 2, 2026 | Stacy Lindborg President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +56,187 | $0.00 | $0 | 56,187 | Jan 6, 2026 |
| Jan 2, 2026 | Christine A Pellizzari director | AGrant or award Stock Option (Right to Buy)derivative | +4,827 | $0.00 | $0 | 4,827 | Jan 6, 2026 |
| Jan 2, 2026 | Michael H Tardugno Executive Chairman of Board | AGrant or award Stock Option (Right to Buy)derivative | +43,821 | $0.00 | $0 | 43,821 | Jan 6, 2026 |
| Sep 6, 2025 | Stacy Lindborg President and CEO | MOption exercise Common Stock | +1,667 | $0.00 | $0 | 3,584 | Sep 9, 2025 |
| Sep 6, 2025 | Stacy Lindborg President and CEO | MOption exercise Restricted Stockderivative | -1,667 | $0.00 | $0 | 0 | Sep 9, 2025 |
| Aug 4, 2025 | Donald P Braun director | AGrant or award Common Stock | +2,040 | $9.20 | $19k | 3,747 | Aug 6, 2025 |
| Aug 4, 2025 | James E Dentzer director | AGrant or award Common Stock | +3,318 | $9.20 | $31k | 3,318 | Aug 6, 2025 |
| Aug 4, 2025 | Susan Eylward General Counsel and Corp Sec | AGrant or award Stock Option (Right to Buy)derivative | +417 | $0.00 | $0 | 417 | Aug 6, 2025 |
| Aug 4, 2025 | Frederick J. Fritz director | AGrant or award Common Stock | +3,161 | $9.20 | $29k | 3,946 | Aug 6, 2025 |
| Aug 4, 2025 | Stacy Lindborg President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Aug 6, 2025 |
| Aug 4, 2025 | Michael H Tardugno Executive Chairman of Board | AGrant or award Stock Option (Right to Buy)derivative | +1,667 | $0.00 | $0 | 1,667 | Aug 6, 2025 |
| Aug 4, 2025 | Christine A Pellizzari director | AGrant or award Common Stock | +2,248 | $9.20 | $21k | 2,248 | Aug 6, 2025 |
| Aug 4, 2025 | Khursheed Anwer Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +1,667 | $0.00 | $0 | 1,667 | Aug 6, 2025 |
| Aug 4, 2025 | Kimberly Bragg CFO | AGrant or award Stock Option (Right to Buy)derivative | +667 | $0.00 | $0 | 667 | Aug 6, 2025 |
| Aug 4, 2025 | Donald P Braun director | AGrant or award Stock Option (Right to Buy)derivative | +250 | $0.00 | $0 | 250 | Aug 6, 2025 |
| Aug 4, 2025 | James E Dentzer director | AGrant or award Stock Option (Right to Buy)derivative | +250 | $0.00 | $0 | 250 | Aug 6, 2025 |
| Aug 4, 2025 | Frederick J. Fritz director | AGrant or award Stock Option (Right to Buy)derivative | +250 | $0.00 | $0 | 250 | Aug 6, 2025 |
| Aug 4, 2025 | Christine A Pellizzari director | AGrant or award Stock Option (Right to Buy)derivative | +250 | $0.00 | $0 | 250 | Aug 6, 2025 |
| Mar 14, 2025 | Donald P Braun director | AGrant or award Stock Option (Right to Buy)derivative | +3,750 | $0.00 | $0 | 3,750 | Mar 18, 2025 |
| Mar 14, 2025 | James E Dentzer director | AGrant or award Stock Option (Right to Buy)derivative | +3,750 | $0.00 | $0 | 3,750 | Mar 18, 2025 |
| Mar 14, 2025 | Susan Eylward General Counsel and Corp Sec | AGrant or award Stock Option (Right to Buy)derivative | +6,250 | $0.00 | $0 | 6,250 | Mar 18, 2025 |
| Mar 14, 2025 | Frederick J. Fritz director | AGrant or award Stock Option (Right to Buy)derivative | +3,750 | $0.00 | $0 | 3,750 | Mar 18, 2025 |
| Mar 14, 2025 | Stacy Lindborg President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Mar 18, 2025 |
| Mar 14, 2024 | Khursheed Anwer Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Mar 18, 2025 |
| Mar 14, 2025 | Christine A Pellizzari director | AGrant or award Stock Option (Right to Buy)derivative | +3,750 | $0.00 | $0 | 3,750 | Mar 18, 2025 |
| Mar 14, 2025 | Michael H Tardugno Executive Chairman of Board | AGrant or award Stock Option (Right to Buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Mar 18, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Khursheed AnwerChief Scientific Officer
- Kimberly BraggCFO
- Donald P Braundirector
- James E Dentzerceo, president, officer, director
- Susan EylwardGeneral Counsel and Corp Sec
- Douglas Vincent FallerChief Medical Officer
- Frederick J. Fritzdirector
- Stacy LindborgPresident and CEO
- Christine A Pellizzaridirector
- Michael H TardugnoExecutive Chairman of Board
Questions about IMNN
Answered from the filings on this page, as of the latest one.
Are insiders buying IMNN?
As of Sep 28, 2026, SEC Form 4 filings show 0 open-market buys worth $0 by 0 insiders and 1 open-market sell worth $3,950 by 1 insider at Imunon, Inc. in the last 90 days, net -$3,950. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade IMNN on the open market?
Susan Eylward (General Counsel and Corp Sec) sold $3,950 of IMNN on Aug 31, 2026 and filed the Form 4 on Sep 1, 2026. InsiderTell scored 25 (weak).
How many insiders file Form 4 at Imunon, Inc.?
10 people have filed a Form 4 at Imunon, Inc., among them Khursheed Anwer (Chief Scientific Officer), Kimberly Bragg (CFO), Donald P Braun (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.